Navigation Links
Oncothyreon to present at the Rodman & Renshaw Annual Global Investment Conference

SEATTLE, May 12 /PRNewswire-FirstCall/ - Oncothyreon Inc. (Nasdaq: ONTY) announced today that Robert Kirkman, M.D., President and Chief Executive Officer, will present at the Rodman & Renshaw Annual Global Investment Conference taking place in London on May 16-18, 2010.

Dr. Kirkman will present at 10:15 a.m. British Summer Time (5:15 a.m. Eastern Daylight Time) on Tuesday, May 18 at the Grosvenor House Hotel. A live and archived webcast of the presentation will be accessible by visiting the Oncothyreon website under the "News & Events" section.

About Oncothyreon

Oncothyreon is a biotechnology company specializing in the development of innovative therapeutic products for the treatment of cancer. Oncothyreon's goal is to develop and commercialize novel synthetic vaccines and targeted small molecules that have the potential to improve the lives and outcomes of cancer patients. For more information, visit

SOURCE Oncothyreon Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. Oncothyreon reports full year and fourth quarter 2009 financial results
2. Oncothyreon reports first quarter 2010 financial results
3. Oncothyreon announces temporary suspension of Stimuvax clinical trials by Merck Serono
4. Oncothyreon consults with Division of Corporation Finance about accounting for 2008 License Agreement
5. Oncothyreons PX-866 PI-3 kinase inhibitor named among Top 10 most promising oncology products for partnering by Windhover
6. Oncothyreon reports third quarter 2009 financial results & provides product pipeline update
7. Oncothyreon announces webcast of third quarter 2009 financial results conference call
8. Oncothyreon announces appointment of Douglas E. Williams, Ph.D., to board of directors
9. Oncothyreon to present at Rodman Renshaw Global Healthcare Conference
10. Oncothyreon reports second quarter 2009 financial results
11. Oncothyreon announces closing of $15.0 million registered direct financing
Post Your Comments:
(Date:10/12/2015)... ... , ... NeuMedics Inc., is a specialty biopharmaceutical company focused on identifying and ... be administered as an eye drop, announced today it has been selected to present ... place October 25th to October 28th at The Cleveland Clinic, Cleveland, Ohio. The ...
(Date:10/11/2015)... ... October 11, 2015 , ... ... has been officially launched and multiple surgeries have been completed with this new ... of the Neuroscience & Spine Center of the Carolinas. The Revolution™ Spinal ...
(Date:10/10/2015)... 10. Oktober, 2015 Am 8. Oktober ... Demokratischen Partei für Kalifornien) ihre Würdigung der International ... in die Aufzeichnungen des Kongresses eintragen lassen. Die ... Association (PPTA) und ihren Mitgliedsunternehmen unterstützt. Ihre ... des Bewusstseins über Plasmaspenden weltweit , Würdigung ...
(Date:10/9/2015)... Governor Tom Wolf announced today that Adaptimmune ... T-cell receptor cancer immunotherapy treatments, will create at least ... Pennsylvania , and today,s announcement ... high-paying jobs will be created with this project," said ... sustained funding for the life science sector and increased ...
Breaking Biology Technology:
(Date:9/24/2015)... 24, 2015 Publiceringsförbud ... Kerv ( ), ... idag världens första kontaktlösa betalningsring på ... 000 GBP för massproduktion via crowdfunding.  ... , Kerv-bärare kan göra direkta ...
(Date:9/10/2015)... 10, 2015 Report Details ... Selling Opportunities and Revenue Prospects to Help You ... biologics, especially new drug classes? Get the latest ... with exclusive market data and industry knowledge, benefitting ... results, opportunities and sales predictions. Visiongain,s new ...
(Date:9/10/2015)... Sept. 10, 2015 Pursuant Health has ... to create an interactive, image-based health risk assessment ... wellness kiosk.  The unique assessment quantifies user results ... that suggests an individual,s biological age based on ... measured by the kiosk. Comprised of ...
Breaking Biology News(10 mins):